Amryt Supports Global EB Awareness Week 2022

Amryt Supports Global EB Awareness Week 2022

DUBLIN, Ireland, and Boston MA, October 24, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a worldwide, commercial-stage biopharmaceutical firm devoted to buying, growing and commercializing novel remedies for uncommon ailments, declares its assist for Global Epidermolysis Bullosa (EB) Awareness Week which is going down October 25 – 31, 2022.

Dr Joe Wiley, CEO of Amryt Pharma, commented: “Epidermolysis Bullosa profoundly impacts the lives of not only the people living with the condition, but also their families and caregivers. In addition to dealing with the painful effects of the disease, the current standard of treatment requires patients and families to endure hours of dressing changes and wound care each day. Amryt is committed to transforming the lives of people affected by rare, debilitating conditions like EB by bringing new treatment options to those in need. We are proud to have the first treatment in the world approved for EB in the EU and are committed to working with other regulatory agencies, including the FDA, to enable more patients to avail of this treatment. EB Awareness Week represents an important opportunity to raise visibility of this devastating condition and the need for expanded treatment options.”

Brett Kopelan, President, Debra of America commented: “When my daughter, Rafi, was first diagnosed with EB at 10 days old, I said this was the worst disease I never heard of, and that statement has become synonymous with the disease.  EB Awareness week is an important time to increase awareness of the disease, the need for direct support and for commercially available treatments.  It’s also a time to demonstrate how EB impacts not only the affected individual, but also their parents and siblings.  Given the potential of a treatment being available in the near future, those with EB no longer just cling to hope, we are expecting better lives for our loved ones.  That’s why we are celebrating this important week this year, but there is always more work to do.”

About Amryt
Amryt is a worldwide commercial-stage biopharmaceutical firm targeted on buying, growing and commercializing progressive remedies to assist enhance the lives of sufferers with uncommon and orphan ailments. Amryt includes a robust and rising portfolio of economic and growth belongings.
  
Amryt’s business business includes 4 orphan illness merchandise – metreleptin (Myalept®/ Myalepta®); oral octreotide (Mycapssa®); lomitapide (Juxtapid®/ Lojuxta®); and Oleogel-S10 (Filsuvez®).

Myalept®/Myalepta® (metreleptin) is authorised within the US (underneath the commerce identify Myalept®) as an adjunct to food plan as alternative remedy to deal with the problems of leptin deficiency in sufferers with congenital or acquired generalized lipodystrophy (GL) and within the EU (underneath the commerce identify Myalepta®) as an adjunct to food plan for the therapy of leptin deficiency in sufferers with congenital or acquired GL in adults and youngsters two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and youngsters 12 years of age and above for whom commonplace remedies have failed to attain ample metabolic management. For extra info, please comply with this hyperlink.

Mycapssa® (octreotide capsules) is authorised within the US for long-term upkeep remedy in acromegaly sufferers who’ve responded to and tolerated therapy with octreotide or lanreotide. Mycapssa® is the primary and solely oral somatostatin analog authorised by the FDA. Mycapssa® has additionally been submitted to the EMA and has acquired a constructive opinion by the CHMP recommending the approval of Mycapssa® within the European Union (EU). For extra info, please comply with this hyperlink.

Juxtapid®/Lojuxta® (lomitapide) is authorised as an adjunct to a low-fat food plan and different lipid-lowering medicinal merchandise for adults with the uncommon ldl cholesterol dysfunction, Homozygous Familial Hypercholesterolaemia (“HoFH”) within the US, Canada, Colombia, Argentina and Japan (underneath the commerce identify Juxtapid®) and within the EU, Israel, Saudi Arabia and Brazil (underneath the commerce identify Lojuxta®). For extra info, please comply with this hyperlink.

Amryt’s pre-clinical gene remedy candidate, AP103, affords a possible therapy for sufferers with Dystrophic EB, and the polymer-based supply platform has the potential to be developed for the therapy of different genetic problems.

Amryt additionally intends to develop oral medicines which can be presently solely obtainable as injectable therapies by its Transient Permeability Enhancer (TPE®) expertise platform. For extra info on Amryt, together with merchandise, please go to www.amrytpharma.com.

Forward-Looking Statements
This announcement could comprise forward-looking statements and the phrases “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project” and related expressions (or their detrimental) establish sure of those forward-looking statements. The forward-looking statements on this announcement are primarily based on quite a few assumptions and Amryt’s current and future business methods and the atmosphere by which Amryt expects to function sooner or later. Forward-looking statements contain inherent identified and unknown dangers, uncertainties and contingencies as a result of they relate to occasions and rely on circumstances which will or could not happen sooner or later and will trigger the precise outcomes, efficiency or achievements to be materially totally different from these expressed or implied by such forward-looking statements. These statements usually are not ensures of future efficiency or the flexibility to establish and consummate investments. Many of those dangers and uncertainties relate to components which can be past Amryt’s capacity to regulate or estimate exactly, resembling future market situations, the course of the COVID-19 pandemic, forex fluctuations, the behaviour of different market members, the result of medical trials, the actions of regulators and different components resembling Amryt’s capacity to acquire financing, adjustments within the political, social and regulatory framework by which Amryt operates or in financial, technological or client developments or situations. Past efficiency shouldn’t be taken as a sign or assure of future outcomes, and no illustration or guarantee, specific or implied, is made relating to future efficiency. No individual is underneath any obligation to replace or hold present the knowledge contained on this announcement or to supply the recipient of it with entry to any extra related info which will come up in reference to it. Such forward-looking statements mirror the Company’s present beliefs and assumptions and are primarily based on info presently obtainable to administration.

Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, [email protected]
Tim McCarthy, LifeSci Advisors, LLC, +1 (917) 679 9282, [email protected]